Initial Workup for Hematuria and Pelvic Pain

Immediate Clinical Assessment

The American Urological Association recommends verifying microscopic hematuria with ≥3 red blood cells per high-power field on properly collected clean-catch midstream specimen 1, 4
Dipstick positivity alone has only 65-99% specificity and requires microscopic confirmation before proceeding with extensive workup 2
The initial workup must include urinalysis with microscopy to confirm true hematuria, urine culture to exclude infection, serum creatinine to assess renal function, and urgent imaging with CT urography plus cystoscopy if gross hematuria is present or if the patient has high-risk features for malignancy 1, 2, 3
Quantify smoking history in pack-years: >30 pack-years represents high risk for urothelial malignancy 2, 3
Document occupational exposures to chemicals, dyes, benzenes, or aromatic amines associated with bladder cancer 1, 3
Characterize the pelvic pain: location, character, severity, relationship to voiding, and duration (symptoms should be present for at least 6 weeks to consider interstitial cystitis/bladder pain syndrome) 5
Assess for irritative voiding symptoms (frequency, urgency, dysuria) which may indicate high-risk conditions including malignancy or IC/BPS 5, 2

Urinalysis with microscopy to confirm hematuria and examine for dysmorphic RBCs, red cell casts, and proteinuria 1, 2, 3
Urine culture (preferably before antibiotics) to exclude urinary tract infection, even with negative dipstick, as lower bacterial levels may be clinically significant 5, 2, 3
Serum creatinine, BUN, and complete metabolic panel to assess renal function and identify medical renal disease 2, 3

Multiphasic CT urography (without and with IV contrast) is the imaging procedure of choice, including sufficient phases to evaluate renal parenchyma for masses and an excretory phase to evaluate upper tract urothelium 1, 2, 3
CT urography has the highest sensitivity and specificity for detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis 1, 2

All patients with gross hematuria to exclude bladder malignancy 2, 3
All patients with risk factors for urinary tract malignancies (irritative voiding symptoms, tobacco use, chemical exposures) regardless of age 1
Suspected Hunner lesions in patients with IC/BPS symptoms, as this is the only reliable way to diagnose these lesions and early diagnosis allows targeted treatment without requiring failure of other therapies first 5

Clinical diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS) requires: symptoms present for at least 6 weeks with documented negative urine cultures, bladder/pelvic pain and pressure/discomfort associated with urinary frequency and strong urge to void 5
Proper hematuria workup should be performed in IC/BPS patients with unevaluated hematuria, and considered in those with tobacco exposure given high bladder cancer risk in smokers 5

Never dismiss hematuria in patients on anticoagulation or antiplatelet therapy: these medications unmask underlying pathology but do not cause hematuria and should not defer evaluation 1, 2, 3
Never accept self-limited gross hematuria as benign: 30-40% harbor malignancy and require complete evaluation 2, 3
Never attribute hematuria to BPH without complete evaluation: malignancy can coexist 3
Never delay evaluation for urinary tract infection: exclude infection but recognize malignancy can coexist 3
Blood at urethral meatus with pelvic fracture: perform retrograde urethrography before catheter placement 7, 8